On Wednesday, Eldorado Gold Corporation (NYSE:EGO)’s shares surged 4.93% to $5.11.
Eldorado Gold Corporation, will release its Q1 2015 Financial Results after the market closes on Thursday April 30, 2015. Paul Wright, Chief Executive Officer of the Company, will host a conference call on Friday May 1, 2015 at 8:30 AM PT (11:30 AM ET).
Eldorado Gold Corporation, together with its auxiliaries, engages in the exploration, discovery, development, production, and reclamation of gold properties, primarily in Brazil, China, Greece, Turkey, and Romania. It also explores for iron, silver, lead, zinc, and copper ores.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s shares gained 4.90% to $4.71, during the last trading session on Wednesday.
Arena Pharmaceuticals, and Eisai Inc. declared the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as contrast to the twice-daily immediate release formulation approved by the US Food and Drug Administration (FDA) and marketed as BELVIQ®. If approved, the extended release formulation is predictable to be marketed as BELVIQ XR, which is the brand name conditionally approved by the FDA.
Each of the two randomized, crossover trials evaluated the safety, tolerability, pharmacokinetics and bioavailability of an extended release formulation of lorcaserin in 36 healthy adult subjects. Patients in each trial were divided into two treatment groups and received both doses in a two-way crossover sequence. Patients in the first study were dosed under fasted conditions either 10 mg twice-daily (BID) immediate release or 20 mg once-daily (QD) extended release. Patients in the second study were dosed either 20 mg QD extended release in the fasted state or 20 mg QD extended release in the fed state.
The most common treatment-emergent adverse events were similar to those seen in the Phase 3 clinical trials of BELVIQ, and comprised of mild or moderate headache, constipation, dizziness and nausea. There were no discontinuations for adverse events, and no serious adverse events were observed.
Lorcaserin extended release formulation is investigational and not approved by any regulatory agency.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.
At the end of Wednesday’s trade, Frank’s International N.V. (NYSE:FI)’s shares gained 4.72% to $19.98.
Frank’s International, declared that it will host a conference call to talk about first quarter 2015 results on Wednesday, April 29, 2015 at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). The Company will release its first quarter 2015 earnings release preceding to the conference call.
Frank’s International N.V. provides various engineered tubular services for the oil and gas exploration and production companies in the United States and internationally. The company’s tubular services comprise the handling and installation of multiple joints of pipe to establish a cased wellbore; and the installation of smaller diameter pipe inside a cased wellbore to provide a conduit for produced oil and gas to reach the surface.
Finally, Patterson-UTI Energy Inc. (NASDAQ:PTEN), ended its Wednesday’s trading session with 4.70% gain, and closed at $22.49, as oil prices continued to gain Wednesday.
The U.S. Energy Information Administration said crude oil stockpiles climbed 1.3 million barrels to 483.7 million barrels in the week ended April 10. Analysts surveyed by the Wall Street Journal had predictable a rise of 3.6 million barrels.
Still, stockpiles remain at their highest level in about 80 years, according to the EIA.
Patterson-UTI Energy, Inc., through its auxiliaries, provides onshore contract drilling services to major and independent oil and natural gas operators in the United States and Canada. The company operates through three segments: Contract Drilling, Pressure Pumping, and Oil and Natural Gas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
